# MicroRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma

**Authors:** Ana Kober Leite, Kelly Cristina Saito, Thérèse Rachell Theodoro, Fátima Solange Pasini, Venâncio Avancini Ferreira Alves, Luiz Paulo Kowalski, Maria Aparecida Silva Pinhal, Gilberto Mendes Junior Menderico, Edna Teruko Kimura, Leandro Luongo Matos

PMC · DOI: 10.1007/s12020-025-04510-6 · Endocrine · 2026-03-09

## TL;DR

This study identifies specific microRNA patterns linked to poor treatment response and aggressive tumor behavior in advanced thyroid cancer, suggesting potential for improved diagnosis and treatment strategies.

## Contribution

The study identifies novel miRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma.

## Key findings

- Lower miR-200c-3p expression is independently associated with radioiodine refractoriness.
- Higher let-7i-5p and miR-19b-3p, and lower miR-31-5p and let-7e-5p, are linked to tumor dedifferentiation.
- miRNA expression signatures clearly segregate patients with different tumor phenotypes.

## Abstract

Radioiodine (RAI) refractoriness and tumor dedifferentiation are major contributors to poor outcomes in metastatic papillary thyroid carcinoma (PTC). microRNAs (miRNAs) are promising biomarkers to identify these aggressive phenotypes. This study aimed to characterize miRNAs expression profiles associated with RAI refractoriness and dedifferentiation.

From a cohort of 108 metastatic PTC patients, 24 cases with available formalin-fixed paraffin-embedded tissue were selected for molecular analysis, including 17 patients who died from disease progression and 7 long-term survivors with stable disease. Total RNA was extracted and analyzed by qPCR. miRNAs with differential expression (P < 0.10) in univariate analysis were included in multivariate linear regression models. Diagnostic performance was assessed using ROC curve analysis and hierarchical clustering.

The cohort had a mean age of 55.2 years and was predominantly male (66.7%). RAI-refractory disease was present in 63.2% of evaluable cases, and dedifferentiation in 33.3%. In multivariate analysis, lower expression of miR-200c-3p was independently associated with RAI refractoriness (P = 0.005). For tumor dedifferentiation, higher expression of let-7i-5p (P < 0.001) and miR-19b-3p (P < 0.001), and lower expression of miR-31-5p (P = 0.004) and let-7e-5p (P = 0.036), were independently associated. ROC curve analysis demonstrated high diagnostic accuracy for miR-200c-3p (AUC = 0.929) and let-7i-5p (AUC = 0.958) for, respectively, RAI refractoriness and tumor dedifferentiation. Heatmap analysis revealed clear segregation of phenotypic groups based on miRNA expression.

Distinct miRNAs signatures are associated with RAI refractoriness and tumor dedifferentiation in metastatic PTC. These findings support their potential as prognostic biomarkers and may guide future therapeutic stratification.

The online version contains supplementary material available at 10.1007/s12020-025-04510-6.

## Linked entities

- **Diseases:** papillary thyroid carcinoma (MONDO:0005075)

## Full-text entities

- **Genes:** MIR106A (microRNA 106a) [NCBI Gene 406899] {aka MIRN106A, mir-106, mir-106a}, MIR554 (microRNA 554) [NCBI Gene 693139] {aka MIRN554, hsa-mir-554}, MIR128-1 (microRNA 128-1) [NCBI Gene 406915] {aka MIR128A, MIRN128-1, MIRN128A, mir-128-1}, MIR2861 (microRNA 2861) [NCBI Gene 100422910] {aka BMND15, MIRN2861}, MIR137 (microRNA 137) [NCBI Gene 406928] {aka MIRN137, miR-137}, MIR503 (microRNA 503) [NCBI Gene 574506] {aka MIRN503, hsa-mir-503, mir-503}, MIR98 (microRNA 98) [NCBI Gene 407054] {aka MIRLET7L, MIRN98, hsa-mir-98, miR-98}, MIR572 (microRNA 572) [NCBI Gene 693157] {aka MIRN572, hsa-mir-572}, MIR1295A (microRNA 1295a) [NCBI Gene 100302178] {aka MIR1295, MIRN1295, hsa-mir-1295, hsa-mir-1295a, mir-1295a}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, MIR34C (microRNA 34c) [NCBI Gene 407042] {aka MIRN34C, miRNA34C, mir-34c}, MIR4788 (microRNA 4788) [NCBI Gene 100616281], MIR17 (microRNA 17) [NCBI Gene 406952] {aka MIR17-5p, MIR91, MIRN17, MIRN91, hsa-mir-17, miR-17}, MIR302C (microRNA 302c) [NCBI Gene 442895] {aka MIRN302C, mir-302c}, MIR18A (microRNA 18a) [NCBI Gene 406953] {aka C13orf25, MIR18, MIRH1, MIRHG1, MIRN18, MIRN18A}, MIR455 (microRNA 455) [NCBI Gene 619556] {aka MIRN455, hsa-mir-455, mir-455}, MIR33B (microRNA 33b) [NCBI Gene 693120] {aka MIRN33B, hsa-mir-33b, mir-33b}, MIR500A (microRNA 500a) [NCBI Gene 574502] {aka MIR500, MIRN500, hsa-mir-500, hsa-mir-500a, mir-500a}, MIR1249 (microRNA 1249) [NCBI Gene 100302149] {aka MIRN1249, hsa-mir-1249}, MIR146B (microRNA 146b) [NCBI Gene 574447] {aka MIRN146B, miRNA146B, mir-146b}, SLC5A5 (solute carrier family 5 member 5) [NCBI Gene 6528] {aka NIS, TDH1}, MIR200C (microRNA 200c) [NCBI Gene 406985] {aka MIRN200C, mir-200c}, MIR34B (microRNA 34b) [NCBI Gene 407041] {aka MIRN34B, miRNA34B, mir-34b}, MIR138-2 (microRNA 138-2) [NCBI Gene 406930] {aka MIRN138-2, mir-138-2}, MIR506 (microRNA 506) [NCBI Gene 574511] {aka MIRN506, hsa-mir-506, mir-506}, MIR19B1 (microRNA 19b-1) [NCBI Gene 406980] {aka C13orf25, MIR19B, MIRH1, MIRHG1, MIRN19B1, miR-19b-1}, MIR130B (microRNA 130b) [NCBI Gene 406920] {aka MIRN130B, mir-130b}, MIRLET7I (microRNA let-7i) [NCBI Gene 406891] {aka LET7I, MIRNLET7I, hsa-let-7i, let-7i}, MIRLET7E (microRNA let-7e) [NCBI Gene 406887] {aka LET7E, MIRNLET7E, hsa-let-7e, let-7e}, MIR30E (microRNA 30e) [NCBI Gene 407034] {aka MIR30E*, MIRN30E, mir-30e}, MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, MIR204 (microRNA 204) [NCBI Gene 406987] {aka MIRN204, RDICC, miRNA204, mir-204}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, MIR1915 (microRNA 1915) [NCBI Gene 100302129] {aka MIRN1915, hsa-mir-1915}, MIR31 (microRNA 31) [NCBI Gene 407035] {aka MIRN31, hsa-mir-31, miR-31}, MIR187 (microRNA 187) [NCBI Gene 406963] {aka MIRN187, miR-187, miRNA187}, MIR3196 (microRNA 3196) [NCBI Gene 100423014] {aka mir-3196}
- **Diseases:** DM (MESH:D009362), thyroid cancer (MESH:D013964), death (MESH:D003643), disease (MESH:D004194), Cancer (MESH:D009369), metastatic disease (MESH:D000092182), RRD (MESH:D000069279), PTC (MESH:D000077273)
- **Chemicals:** RAI (-), Iodine-131 (MESH:C000614965), Iodine (MESH:D007455), formalin (MESH:D005557), paraffin (MESH:D010232)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** V600E, AUC of 0

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12971732/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12971732/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12971732/full.md

---
Source: https://tomesphere.com/paper/PMC12971732